Glass Microspheres
The research report includes specific segments by region (country), by manufacturers, by Type and ... Read More
Global Non-alcoholic Steatohepatitis Market Research Report 2023
1 Non-alcoholic Steatohepatitis Market Overview
1.1 Product Overview and Scope of Non-alcoholic Steatohepatitis
1.2 Non-alcoholic Steatohepatitis Segment by Type
1.2.1 Global Non-alcoholic Steatohepatitis Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Solid
1.2.3 Liquid
1.3 Non-alcoholic Steatohepatitis Segment by Application
1.3.1 Global Non-alcoholic Steatohepatitis Sales Comparison by Application: (2022-2028)
1.3.2 Oral
1.3.3 Parenteral
1.4 Global Non-alcoholic Steatohepatitis Market Size Estimates and Forecasts
1.4.1 Global Non-alcoholic Steatohepatitis Revenue 2017-2028
1.4.2 Global Non-alcoholic Steatohepatitis Sales 2017-2028
1.4.3 Non-alcoholic Steatohepatitis Market Size by Region: 2017 Versus 2021 Versus 2028
2 Non-alcoholic Steatohepatitis Market Competition by Manufacturers
2.1 Global Non-alcoholic Steatohepatitis Sales Market Share by Manufacturers (2017-2022)
2.2 Global Non-alcoholic Steatohepatitis Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Non-alcoholic Steatohepatitis Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Non-alcoholic Steatohepatitis Manufacturing Sites, Area Served, Product Type
2.5 Non-alcoholic Steatohepatitis Market Competitive Situation and Trends
2.5.1 Non-alcoholic Steatohepatitis Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Non-alcoholic Steatohepatitis Players Market Share by Revenue
2.5.3 Global Non-alcoholic Steatohepatitis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Non-alcoholic Steatohepatitis Retrospective Market Scenario by Region
3.1 Global Non-alcoholic Steatohepatitis Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Non-alcoholic Steatohepatitis Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Non-alcoholic Steatohepatitis Market Facts & Figures by Country
3.3.1 North America Non-alcoholic Steatohepatitis Sales by Country
3.3.2 North America Non-alcoholic Steatohepatitis Revenue by Country
3.3.3 the United States
3.3.4 Canada
3.4 Europe Non-alcoholic Steatohepatitis Market Facts & Figures by Country
3.4.1 Europe Non-alcoholic Steatohepatitis Sales by Country
3.4.2 Europe Non-alcoholic Steatohepatitis Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 UK
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Non-alcoholic Steatohepatitis Market Facts & Figures by Region
3.5.1 Asia Pacific Non-alcoholic Steatohepatitis Sales by Region
3.5.2 Asia Pacific Non-alcoholic Steatohepatitis Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Non-alcoholic Steatohepatitis Market Facts & Figures by Country
3.6.1 Latin America Non-alcoholic Steatohepatitis Sales by Country
3.6.2 Latin America Non-alcoholic Steatohepatitis Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Non-alcoholic Steatohepatitis Market Facts & Figures by Country
3.7.1 Middle East and Africa Non-alcoholic Steatohepatitis Sales by Country
3.7.2 Middle East and Africa Non-alcoholic Steatohepatitis Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Non-alcoholic Steatohepatitis Historic Market Analysis by Type
4.1 Global Non-alcoholic Steatohepatitis Sales Market Share by Type (2017-2022)
4.2 Global Non-alcoholic Steatohepatitis Revenue Market Share by Type (2017-2022)
4.3 Global Non-alcoholic Steatohepatitis Price by Type (2017-2022)
5 Global Non-alcoholic Steatohepatitis Historic Market Analysis by Application
5.1 Global Non-alcoholic Steatohepatitis Sales Market Share by Application (2017-2022)
5.2 Global Non-alcoholic Steatohepatitis Revenue Market Share by Application (2017-2022)
5.3 Global Non-alcoholic Steatohepatitis Price by Application (2017-2022)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.1.4 AstraZeneca Non-alcoholic Steatohepatitis Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Arena Pharmaceuticals
6.2.1 Arena Pharmaceuticals Corporation Information
6.2.2 Arena Pharmaceuticals Description and Business Overview
6.2.3 Arena Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Arena Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolio
6.2.5 Arena Pharmaceuticals Recent Developments/Updates
6.3 GSK
6.3.1 GSK Corporation Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.3.4 GSK Non-alcoholic Steatohepatitis Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 Novo Nordisk
6.4.1 Novo Nordisk Corporation Information
6.4.2 Novo Nordisk Description and Business Overview
6.4.3 Novo Nordisk Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Novo Nordisk Non-alcoholic Steatohepatitis Product Portfolio
6.4.5 Novo Nordisk Recent Developments/Updates
6.5 Roche
6.5.1 Roche Corporation Information
6.5.2 Roche Description and Business Overview
6.5.3 Roche Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Roche Non-alcoholic Steatohepatitis Product Portfolio
6.5.5 Roche Recent Developments/Updates
6.6 Vivus
6.6.1 Vivus Corporation Information
6.6.2 Vivus Description and Business Overview
6.6.3 Vivus Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Vivus Non-alcoholic Steatohepatitis Product Portfolio
6.6.5 Vivus Recent Developments/Updates
6.7 Arisaph Pharmaceuticals
6.6.1 Arisaph Pharmaceuticals Corporation Information
6.6.2 Arisaph Pharmaceuticals Description and Business Overview
6.6.3 Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolio
6.7.5 Arisaph Pharmaceuticals Recent Developments/Updates
6.8 Cempra Pharmaceuticals
6.8.1 Cempra Pharmaceuticals Corporation Information
6.8.2 Cempra Pharmaceuticals Description and Business Overview
6.8.3 Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolio
6.8.5 Cempra Pharmaceuticals Recent Developments/Updates
6.9 Galectin Therapeutics
6.9.1 Galectin Therapeutics Corporation Information
6.9.2 Galectin Therapeutics Description and Business Overview
6.9.3 Galectin Therapeutics Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Galectin Therapeutics Non-alcoholic Steatohepatitis Product Portfolio
6.9.5 Galectin Therapeutics Recent Developments/Updates
6.10 Galmed Pharmaceuticals
6.10.1 Galmed Pharmaceuticals Corporation Information
6.10.2 Galmed Pharmaceuticals Description and Business Overview
6.10.3 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Product Portfolio
6.10.5 Galmed Pharmaceuticals Recent Developments/Updates
6.11 Genfit
6.11.1 Genfit Corporation Information
6.11.2 Genfit Non-alcoholic Steatohepatitis Description and Business Overview
6.11.3 Genfit Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Genfit Non-alcoholic Steatohepatitis Product Portfolio
6.11.5 Genfit Recent Developments/Updates
6.12 Gilead
6.12.1 Gilead Corporation Information
6.12.2 Gilead Non-alcoholic Steatohepatitis Description and Business Overview
6.12.3 Gilead Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.12.4 Gilead Non-alcoholic Steatohepatitis Product Portfolio
6.12.5 Gilead Recent Developments/Updates
6.13 Immuron
6.13.1 Immuron Corporation Information
6.13.2 Immuron Non-alcoholic Steatohepatitis Description and Business Overview
6.13.3 Immuron Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.13.4 Immuron Non-alcoholic Steatohepatitis Product Portfolio
6.13.5 Immuron Recent Developments/Updates
6.14 Interceptpharma
6.14.1 Interceptpharma Corporation Information
6.14.2 Interceptpharma Non-alcoholic Steatohepatitis Description and Business Overview
6.14.3 Interceptpharma Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.14.4 Interceptpharma Non-alcoholic Steatohepatitis Product Portfolio
6.14.5 Interceptpharma Recent Developments/Updates
6.15 Raptor Pharmaceutical
6.15.1 Raptor Pharmaceutical Corporation Information
6.15.2 Raptor Pharmaceutical Non-alcoholic Steatohepatitis Description and Business Overview
6.15.3 Raptor Pharmaceutical Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.15.4 Raptor Pharmaceutical Non-alcoholic Steatohepatitis Product Portfolio
6.15.5 Raptor Pharmaceutical Recent Developments/Updates
6.16 Takeda
6.16.1 Takeda Corporation Information
6.16.2 Takeda Non-alcoholic Steatohepatitis Description and Business Overview
6.16.3 Takeda Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.16.4 Takeda Non-alcoholic Steatohepatitis Product Portfolio
6.16.5 Takeda Recent Developments/Updates
6.17 Tobira Therapeutics
6.17.1 Tobira Therapeutics Corporation Information
6.17.2 Tobira Therapeutics Non-alcoholic Steatohepatitis Description and Business Overview
6.17.3 Tobira Therapeutics Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.17.4 Tobira Therapeutics Non-alcoholic Steatohepatitis Product Portfolio
6.17.5 Tobira Therapeutics Recent Developments/Updates
6.18 Verva
6.18.1 Verva Corporation Information
6.18.2 Verva Non-alcoholic Steatohepatitis Description and Business Overview
6.18.3 Verva Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.18.4 Verva Non-alcoholic Steatohepatitis Product Portfolio
6.18.5 Verva Recent Developments/Updates
6.19 Viking Therapeutics
6.19.1 Viking Therapeutics Corporation Information
6.19.2 Viking Therapeutics Non-alcoholic Steatohepatitis Description and Business Overview
6.19.3 Viking Therapeutics Non-alcoholic Steatohepatitis Sales, Revenue and Gross Margin (2017-2022)
6.19.4 Viking Therapeutics Non-alcoholic Steatohepatitis Product Portfolio
6.19.5 Viking Therapeutics Recent Developments/Updates
7 Non-alcoholic Steatohepatitis Manufacturing Cost Analysis
7.1 Non-alcoholic Steatohepatitis Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Non-alcoholic Steatohepatitis
7.4 Non-alcoholic Steatohepatitis Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Non-alcoholic Steatohepatitis Distributors List
8.3 Non-alcoholic Steatohepatitis Customers
9 Non-alcoholic Steatohepatitis Market Dynamics
9.1 Non-alcoholic Steatohepatitis Industry Trends
9.2 Non-alcoholic Steatohepatitis Market Drivers
9.3 Non-alcoholic Steatohepatitis Market Challenges
9.4 Non-alcoholic Steatohepatitis Market Restraints
10 Global Market Forecast
10.1 Non-alcoholic Steatohepatitis Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Non-alcoholic Steatohepatitis by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Non-alcoholic Steatohepatitis by Type (2023-2028)
10.2 Non-alcoholic Steatohepatitis Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Non-alcoholic Steatohepatitis by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Non-alcoholic Steatohepatitis by Application (2023-2028)
10.3 Non-alcoholic Steatohepatitis Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Non-alcoholic Steatohepatitis by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Non-alcoholic Steatohepatitis by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Non-alcoholic Steatohepatitis Sales Growth Rate Comparison by Type (2022-2028) & (MT) & (US$ Million)
Table 2. Global Non-alcoholic Steatohepatitis Sales Growth Rate Comparison by Application (2022-2028) & (MT) & (US$ Million)
Table 3. Global Non-alcoholic Steatohepatitis Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Non-alcoholic Steatohepatitis Market Competitive Situation by Manufacturers in 2021
Table 5. Global Non-alcoholic Steatohepatitis Sales (MT) of Key Manufacturers (2017-2022)
Table 6. Global Non-alcoholic Steatohepatitis Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Non-alcoholic Steatohepatitis Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Non-alcoholic Steatohepatitis Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Non-alcoholic Steatohepatitis Average Price (USD/Kg) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Non-alcoholic Steatohepatitis Manufacturing Sites and Area Served
Table 11. Manufacturers Non-alcoholic Steatohepatitis Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Non-alcoholic Steatohepatitis by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-alcoholic Steatohepatitis as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Non-alcoholic Steatohepatitis Sales by Region (2017-2022) & (MT)
Table 16. Global Non-alcoholic Steatohepatitis Sales Market Share by Region (2017-2022)
Table 17. Global Non-alcoholic Steatohepatitis Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Non-alcoholic Steatohepatitis Revenue Market Share by Region (2017-2022)
Table 19. North America Non-alcoholic Steatohepatitis Sales by Country (2017-2022) & (MT)
Table 20. North America Non-alcoholic Steatohepatitis Sales Market Share by Country (2017-2022)
Table 21. North America Non-alcoholic Steatohepatitis Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Non-alcoholic Steatohepatitis Revenue Market Share by Country (2017-2022)
Table 23. Europe Non-alcoholic Steatohepatitis Sales by Country (2017-2022) & (MT)
Table 24. Europe Non-alcoholic Steatohepatitis Sales Market Share by Country (2017-2022)
Table 25. Europe Non-alcoholic Steatohepatitis Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Non-alcoholic Steatohepatitis Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Non-alcoholic Steatohepatitis Sales by Region (2017-2022) & (MT)
Table 28. Asia Pacific Non-alcoholic Steatohepatitis Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Non-alcoholic Steatohepatitis Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Non-alcoholic Steatohepatitis Revenue Market Share by Region (2017-2022)
Table 31. Latin America Non-alcoholic Steatohepatitis Sales by Country (2017-2022) & (MT)
Table 32. Latin America Non-alcoholic Steatohepatitis Sales Market Share by Country (2017-2022)
Table 33. Latin America Non-alcoholic Steatohepatitis Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Non-alcoholic Steatohepatitis Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Non-alcoholic Steatohepatitis Sales by Country (2017-2022) & (MT)
Table 36. Middle East and Africa Non-alcoholic Steatohepatitis Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Non-alcoholic Steatohepatitis Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Non-alcoholic Steatohepatitis Revenue Market Share by Country (2017-2022)
Table 39. Global Non-alcoholic Steatohepatitis Sales by Type (2017-2022) & (MT)
Table 40. Global Non-alcoholic Steatohepatitis Sales Market Share by Type (2017-2022)
Table 41. Global Non-alcoholic Steatohepatitis Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Non-alcoholic Steatohepatitis Revenue Share by Type (2017-2022)
Table 43. Global Non-alcoholic Steatohepatitis Price by Type (2017-2022) & (USD/Kg)
Table 44. Global Non-alcoholic Steatohepatitis Sales (MT) by Application (2017-2022)
Table 45. Global Non-alcoholic Steatohepatitis Sales Market Share by Application (2017-2022)
Table 46. Global Non-alcoholic Steatohepatitis Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Non-alcoholic Steatohepatitis Revenue Share by Application (2017-2022)
Table 48. Global Non-alcoholic Steatohepatitis Price by Application (2017-2022) & (USD/Kg)
Table 49. AstraZeneca Corporation Information
Table 50. AstraZeneca Description and Business Overview
Table 51. AstraZeneca Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 52. AstraZeneca Non-alcoholic Steatohepatitis Product
Table 53. AstraZeneca Recent Developments/Updates
Table 54. Arena Pharmaceuticals Corporation Information
Table 55. Arena Pharmaceuticals Description and Business Overview
Table 56. Arena Pharmaceuticals Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 57. Arena Pharmaceuticals Non-alcoholic Steatohepatitis Product
Table 58. Arena Pharmaceuticals Recent Developments/Updates
Table 59. GSK Corporation Information
Table 60. GSK Description and Business Overview
Table 61. GSK Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 62. GSK Non-alcoholic Steatohepatitis Product
Table 63. GSK Recent Developments/Updates
Table 64. Novo Nordisk Corporation Information
Table 65. Novo Nordisk Description and Business Overview
Table 66. Novo Nordisk Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 67. Novo Nordisk Non-alcoholic Steatohepatitis Product
Table 68. Novo Nordisk Recent Developments/Updates
Table 69. Roche Corporation Information
Table 70. Roche Description and Business Overview
Table 71. Roche Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 72. Roche Non-alcoholic Steatohepatitis Product
Table 73. Roche Recent Developments/Updates
Table 74. Vivus Corporation Information
Table 75. Vivus Description and Business Overview
Table 76. Vivus Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 77. Vivus Non-alcoholic Steatohepatitis Product
Table 78. Vivus Recent Developments/Updates
Table 79. Arisaph Pharmaceuticals Corporation Information
Table 80. Arisaph Pharmaceuticals Description and Business Overview
Table 81. Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 82. Arisaph Pharmaceuticals Non-alcoholic Steatohepatitis Product
Table 83. Arisaph Pharmaceuticals Recent Developments/Updates
Table 84. Cempra Pharmaceuticals Corporation Information
Table 85. Cempra Pharmaceuticals Description and Business Overview
Table 86. Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 87. Cempra Pharmaceuticals Non-alcoholic Steatohepatitis Product
Table 88. Cempra Pharmaceuticals Recent Developments/Updates
Table 89. Galectin Therapeutics Corporation Information
Table 90. Galectin Therapeutics Description and Business Overview
Table 91. Galectin Therapeutics Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 92. Galectin Therapeutics Non-alcoholic Steatohepatitis Product
Table 93. Galectin Therapeutics Recent Developments/Updates
Table 94. Galmed Pharmaceuticals Corporation Information
Table 95. Galmed Pharmaceuticals Description and Business Overview
Table 96. Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 97. Galmed Pharmaceuticals Non-alcoholic Steatohepatitis Product
Table 98. Galmed Pharmaceuticals Recent Developments/Updates
Table 99. Genfit Corporation Information
Table 100. Genfit Description and Business Overview
Table 101. Genfit Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 102. Genfit Non-alcoholic Steatohepatitis Product
Table 103. Genfit Recent Developments/Updates
Table 104. Gilead Corporation Information
Table 105. Gilead Description and Business Overview
Table 106. Gilead Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 107. Gilead Non-alcoholic Steatohepatitis Product
Table 108. Gilead Recent Developments/Updates
Table 109. Immuron Corporation Information
Table 110. Immuron Description and Business Overview
Table 111. Immuron Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 112. Immuron Non-alcoholic Steatohepatitis Product
Table 113. Immuron Recent Developments/Updates
Table 114. Interceptpharma Corporation Information
Table 115. Interceptpharma Description and Business Overview
Table 116. Interceptpharma Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 117. Interceptpharma Non-alcoholic Steatohepatitis Product
Table 118. Interceptpharma Recent Developments/Updates
Table 119. Raptor Pharmaceutical Corporation Information
Table 120. Raptor Pharmaceutical Description and Business Overview
Table 121. Raptor Pharmaceutical Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 122. Raptor Pharmaceutical Non-alcoholic Steatohepatitis Product
Table 123. Raptor Pharmaceutical Recent Developments/Updates
Table 124. Takeda Corporation Information
Table 125. Takeda Description and Business Overview
Table 126. Takeda Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 127. Takeda Non-alcoholic Steatohepatitis Product
Table 128. Takeda Recent Developments/Updates
Table 129. Tobira Therapeutics Corporation Information
Table 130. Tobira Therapeutics Description and Business Overview
Table 131. Tobira Therapeutics Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 132. Tobira Therapeutics Non-alcoholic Steatohepatitis Product
Table 133. Tobira Therapeutics Recent Developments/Updates
Table 134. Verva Corporation Information
Table 135. Verva Description and Business Overview
Table 136. Verva Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 137. Verva Non-alcoholic Steatohepatitis Product
Table 138. Verva Recent Developments/Updates
Table 139. Viking Therapeutics Corporation Information
Table 140. Viking Therapeutics Description and Business Overview
Table 141. Viking Therapeutics Non-alcoholic Steatohepatitis Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2017-2022)
Table 142. Viking Therapeutics Non-alcoholic Steatohepatitis Product
Table 143. Viking Therapeutics Recent Developments/Updates
Table 144. Production Base and Market Concentration Rate of Raw Material
Table 145. Key Suppliers of Raw Materials
Table 146. Non-alcoholic Steatohepatitis Distributors List
Table 147. Non-alcoholic Steatohepatitis Customers List
Table 148. Non-alcoholic Steatohepatitis Market Trends
Table 149. Non-alcoholic Steatohepatitis Market Drivers
Table 150. Non-alcoholic Steatohepatitis Market Challenges
Table 151. Non-alcoholic Steatohepatitis Market Restraints
Table 152. Global Non-alcoholic Steatohepatitis Sales Forecast by Type (2023-2028) & (MT)
Table 153. Global Non-alcoholic Steatohepatitis Sales Market Share Forecast by Type (2023-2028)
Table 154. Global Non-alcoholic Steatohepatitis Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 155. Global Non-alcoholic Steatohepatitis Revenue Market Share Forecast by Type (2023-2028)
Table 156. Global Non-alcoholic Steatohepatitis Sales Forecast by Application (2023-2028) & (MT)
Table 157. Global Non-alcoholic Steatohepatitis Sales Market Share Forecast by Application (2023-2028)
Table 158. Global Non-alcoholic Steatohepatitis Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 159. Global Non-alcoholic Steatohepatitis Revenue Market Share Forecast by Application (2023-2028)
Table 160. Global Non-alcoholic Steatohepatitis Sales Forecast by Region (2023-2028) & (MT)
Table 161. Global Non-alcoholic Steatohepatitis Sales Market Share Forecast by Region (2023-2028)
Table 162. Global Non-alcoholic Steatohepatitis Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 163. Global Non-alcoholic Steatohepatitis Revenue Market Share Forecast by Region (2023-2028)
Table 164. Research Programs/Design for This Report
Table 165. Key Data Information from Secondary Sources
Table 166. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Non-alcoholic Steatohepatitis
Figure 2. Global Non-alcoholic Steatohepatitis Market Share by Type in 2021 & 2028
Figure 3. Solid Product Picture
Figure 4. Liquid Product Picture
Figure 5. Global Non-alcoholic Steatohepatitis Market Share by Application in 2021 & 2028
Figure 6. Oral
Figure 7. Parenteral
Figure 8. Global Non-alcoholic Steatohepatitis Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 9. Global Non-alcoholic Steatohepatitis Market Size (2017-2028) & (US$ Million)
Figure 10. Global Non-alcoholic Steatohepatitis Sales (2017-2028) & (MT)
Figure 11. Non-alcoholic Steatohepatitis Sales Share by Manufacturers in 2021
Figure 12. Global Non-alcoholic Steatohepatitis Revenue Share by Manufacturers in 2021
Figure 13. The Global 5 and 10 Largest Non-alcoholic Steatohepatitis Players: Market Share by Revenue in 2021
Figure 14. Non-alcoholic Steatohepatitis Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 15. Global Non-alcoholic Steatohepatitis Sales Market Share by Region (2017-2022)
Figure 16. Global Non-alcoholic Steatohepatitis Sales Market Share by Region in 2021
Figure 17. Global Non-alcoholic Steatohepatitis Revenue Market Share by Region (2017-2022)
Figure 18. Global Non-alcoholic Steatohepatitis Revenue Market Share by Region in 2021
Figure 19. the United States Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 20. Canada Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 21. Germany Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. France Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. UK Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. Italy Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Russia Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. China Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Japan Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. South Korea Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. India Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Australia Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. China Taiwan Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Indonesia Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Thailand Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Malaysia Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Mexico Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Brazil Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Argentina Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Turkey Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Saudi Arabia Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. UAE Non-alcoholic Steatohepatitis Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Sales Market Share of Non-alcoholic Steatohepatitis by Type (2017-2022)
Figure 42. Manufacturing Cost Structure of Non-alcoholic Steatohepatitis
Figure 43. Manufacturing Process Analysis of Non-alcoholic Steatohepatitis
Figure 44. Non-alcoholic Steatohepatitis Industrial Chain Analysis
Figure 45. Channels of Distribution
Figure 46. Distributors Profiles
Figure 47. Bottom-up and Top-down Approaches for This Report
Figure 48. Data Triangulation
Figure 49. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
AstraZeneca Arena Pharmaceuticals GSK Novo Nordisk Roche Vivus Arisaph Pharmaceuticals Cempra Pharmaceuticals Galectin Therapeutics Galmed Pharmaceuticals Genfit Gilead Immuron Interceptpharma Raptor Pharmaceutical Takeda Tobira Therapeutics Verva Viking Therapeutics